Altimmune, Inc. Class Action Lawsuit
ALTIMMUNE, INC. INVESTORS: Pending Lead Plaintiff Deadline in ALT Securities Fraud Class Action; Stockholders Should Contact Robbins LLP for Information
20. Juni 2024 13:12 ET | Robbins LLP
Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug
Altimmune, Inc. Class Action Lawsuit
ALT Stockholders: Robbins LLP Reminds ALT Stockholders of Securities Fraud Class Action Against Altimmune, Inc.
23. Mai 2024 17:29 ET | Robbins LLP
Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug
Altimmune, Inc. Class Action Lawsuit
Altimmune, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Altimmune, Inc. (ALT) Class Action
15. Mai 2024 14:43 ET | Robbins LLP
Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug
Altimmune, Inc. Class Action Lawsuit
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Altimmune, Inc. (ALT)
08. Mai 2024 14:02 ET | Robbins LLP
Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug